 KB Home (NYSE: KBH) is not out of the weeds, with its revenue contracting, orders and backlog declining, and margins under pressure, but these forces... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ |
Good MorningStocks finished mixed Wednesday, with the Dow notching a gain while the S&P 500 and Nasdaq closed lower as the tech selloff continued. Major ETFs tied to the S&P 500 and Nasdaq 100 reversed early strength, while lower oil prices helped lift airline stocks and supported a rotation away from some recent AI winners.
Micron was the post-close standout after reporting record fiscal third-quarter results and stronger guidance, with AI-driven memory demand reinforcing the case for firmer pricing and tighter supply. Shares rose after hours. Broadcom also gained after OpenAI unveiled Jalapeño, an AI inference chip developed with Broadcom, while IBM moved higher after joining OpenAI’s cybersecurity partner program. Still, pressure remained on Oracle and Palantir, both caught in the broader debate over AI spending, valuation, and earnings quality.
Outside megacap tech, homebuilders rallied after Congress passed a bipartisan housing package aimed at boosting supply and lowering construction costs, though the bill still faced a White House signing delay. American Airlines, United and JetBlue climbed as falling fuel costs improved sentiment toward carriers. Bath & Body Works gained from a new Ulta Beauty partnership, while AT&T remained under regulatory scrutiny as California officials pushed back on its copper-network retirement plans. Featured: Democrats now hold both chambers. Where does that leave savers? (Ad) 
| Consumer Discretionary | |
KB Home (NYSE: KBH) is not out of the weeds, with its revenue contracting, orders and backlog declining, and margins under pressure, but these forces are already priced into its stock. Housing market woes, inflation, and high interest rates are no secret.
The market has had ample opportunity to adj... Read the Full Story |
| From Our Partners | | A Democratic Congress, a Republican President and a mountain of federal debt that didn't disappear on Election Day. Another debt ceiling standoff could be just around the corner.
Reagan Gold Group's free guide explains why physical gold is back in the retirement conversation and what it means for savings left on autopilot.
Reagan Gold Group is not a financial or tax advisor and has no fiduciary obligations to its clients. | | Request your free guide from Reagan Gold Group to see why gold is back. |
| Communication Services | |
Meta Platform’s (NASDAQ: META) last earnings report disappointed investors, leading shares to fall more than 8% to $611 afterward. This drop has so far indicated the start of a larger slide for the stock, as Meta has continued to tumble, recently falling below $575.
The company’s increased capital... Read the Full Story |
| Consumer Discretionary | |
Shares of Tesla Inc. (NASDAQ: TSLA) are down about 15% from the May high and are starting to take a shape that investors won't want to see. The broader narrative around the company has been getting more interesting by the month, from the Wall Street hype around the company’s full self-driving (FSD)... Read the Full Story |
| From Our Partners | | Money already in an eligible 401(k) or IRA may be used to purchase physical gold through a self-directed gold IRA, which means you may not need to add new funds.
With Washington shifting and uncertainty around inflation and the dollar, more Americans are exploring this option.
Gold isn't immune to losses, and gold IRAs come with fees, rules and risks. Reagan Gold Group is not a financial or tax advisor and has no fiduciary obligations to its clients. | | Request your free guide to self-directed gold IRAs and learn the fees, rules and risks. |
| Industrials | |
Nano Nuclear (NASDAQ: NNE) appears to be the right company for the right time. The company has a goal of building a vertically integrated nuclear business. This goes beyond microreactors to include fuel fabrication, transportation, and other parts of the nuclear supply chain.
The case for nuclear e... Read the Full Story |
| Consumer Discretionary | |
The first round of peace talks aimed at ending the Iran war are in the books, but the damages stemming from the global oil supply shock will linger for years to come.
Prices for Brent crude, the benchmark for two-thirds of the world’s oil, have moderated from their one-year high of around $114 per ... Read the Full Story |
| From Our Partners | | 232 companies listed on U.S. exchanges this year, and 86 priced IPOs had raised over $251 billion by late July alone - more than five times 2025's full-year total. Yet most carry almost no analyst coverage.
We screened the entire class for average daily volume above 500,000 shares, market caps over $100 million, and at least 18 months of cash runway. Only seven names cleared every filter - four already trading, three still private. | | See the seven IPOs that passed every filter. |
| Consumer Staples | |
Several stocks spanning the gamut of high dividend yields to high dividend growth just added more juice to their payments. These stocks hold yields that stretch above 13% at the high end, while also seeing recent dividend increases of up to 14%. This leaves investors with multiple options for how t... Read the Full Story |
| Technology | |
From quantum computing to artificial intelligence to clothing, company insiders are making moves in three key names. This includes sales of a quantum stock that recently popped 50% in two days and a semiconductor industry behemoth posting big-time returns. Meanwhile, insiders are purchasing a cloth... Read the Full Story |
| Technology | |
On June 23, 2026, the equity market delivered a sharp reminder that technology leadership is inseparable from global trade policies. Shares of the Dutch lithography giant ASML Holding N.V. (NASDAQ: ASML) declined by 7.82%, representing a pullback from the all-time high of $1,929.68 reached on June ... Read the Full Story |
| Markets | |
A combination of a weaker U.S. dollar, a push among retail and institutional investors alike toward international investments, and increasing demand for AI exposure have all positioned South Korea as a country to watch in 2026. Companies like Samsung Electronics (OTCMKTS: SSNLF) and SK hynix (NASDA... Read the Full Story |
| Technology | |
Investors looking for high-growth AI infrastructure opportunities have likely watched the recent volatility in Super Micro Computer, Inc. (NASDAQ: SMCI) with a mix of intrigue and anxiety. The central question is whether Supermicro's recent decline represents a warning sign or a buying opportunity.... Read the Full Story |
| Thursday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Wednesday, November 04, 2026 at 6:25 PM.
AbbVie Bull Case -
AbbVie recently secured global rights to Nxera Pharma's experimental oral IBD candidate, NXE0033744, in a deal worth up to $1.47 billion including upfront payments and milestones, which diversifies the company's growth pipeline beyond its current immunology and oncology franchises.
-
The company is investing more than £120 million to expand its Oxford R&D facility, signaling a long-term commitment to advancing research in immunology, neurology, and oncology, which supports future product innovation and market expansion.
-
AbbVie reported strong third-quarter earnings with EPS of $3.82, beating analyst estimates of $3.73, and revenue of $17.40 billion, which was also above the consensus of $17.32 billion, demonstrating robust operational performance and demand for its key products like Skyrizi and Rinvoq.
-
Wall Street sentiment has improved significantly, with multiple brokerages including Morgan Stanley and Piper Sandler raising their price targets, and the stock currently trading at $294.15, which is near its 52-week high of $298.74, reflecting strong investor confidence in the company's trajectory.
-
AbbVie recently increased its quarterly dividend to $1.82 per share, representing a 5.2% increase from the previous $1.73, which provides a growing income stream for investors and signals management's confidence in the company's cash flow generation.
AbbVie Bear Case -
AbbVie discontinued a Phase 2 solid-tumor drug program due to "limited benefit," which is a setback for its oncology pipeline and may raise concerns about the success rate of its other experimental cancer treatments.
-
The company's valuation may be stretched after its recent rally, with a P/E ratio of 50.63, which is high compared to many peers, potentially limiting further upside if growth expectations are not met in the coming quarters.
-
AbbVie's payout ratio is currently 119.10%, meaning the company is paying out more in dividends than it is earning in net income, which could be a concern for long-term sustainability of the dividend if earnings do not grow sufficiently.
-
Insider selling has been notable, with EVP Nicholas Donoghoe selling 32,710 shares in August 2026, representing a 30.53% decrease in his position, which some investors may interpret as a lack of confidence in the stock's near-term performance.
-
Short interest has been relatively high, with 15.58 million shares shorted as of October 2026, which is a significant portion of the float and could indicate that some investors are betting against the stock's future performance.
| | View Today's Stock Pick |
|
| |
|
|
